MedTrace Logo

Ozanimod in Patients With Alzheimer's Disease

NCT06862960 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-07-01

No results posted yet for this study

Summary

The purpose of this study is to investigate the benefits of ozanimod in patients with moderate Alzheimer's disease.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Ozanimod

A sphingosine-1-phosphate receptor regulator

DRUG

Conventional medication

Conventional medications for moderate AD

Sponsors & Collaborators

  • Fujian Medical University Union Hospital

    collaborator OTHER

  • ChenXiaoChun

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2027-06-30
Completion
2027-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06862960 on ClinicalTrials.gov